Background. We examined the epidemiology, clinical manifestations, histopathology, management, and outcomes of gastrointestinal basidiobolomycosis, an uncommon manifestation of infection caused by the fungus Basidiobolus ranarum.
findings, histopathology, management, and outcomes of patients with GIB, as reported in the medical literature, as well as in cases identified at our institution and elsewhere in the United States through March 2010.
METHODS

Definitions
We defined a confirmed case of GIB on the basis of either the characteristic histopathologic appearance of entomophthoromycosis in tissue biopsy or surgical specimens obtained from the gastrointestinal tract or the isolation of B. ranarum from such specimens [10] . We also included 1 patient with chronic diarrhea and repeated isolation of B. ranarum from stool specimens. Gastrointestinal involvement was defined as microscopic or macroscopic involvement of the stomach, small intestine, colon, rectum, liver, gallbladder, or pancreas. Organ involvement was identified on the basis of findings from imaging studies or endoscopy or on the basis of direct observation during surgery. Patients were excluded if they had isolated mesenteric or retroperitoneal disease without gastrointestinal involvement.
Characteristic histopathologic findings were necrotizing granulomatous inflammation, tissue eosinophilia, fungal elements indicative of zygomyces, and evidence of Splendore-Hoeppli phenomenon (ie, fungal hyphae surrounded by radiating, intensely eosinophilic granular material) [10, 11] . After specimen incubation on Sabouraud dextrose agar, B. ranarum colonies were identified by their waxy or yellowish-gray appearance and numerous radial folds. Microscopically, B. ranarum zygospores had a characteristic beaked prominence [10, 12] . Serum samples were analyzed at the CDC for antibodies to B. ranarum, as described elsewhere [13] . Antifungal susceptibility testing of B. ranarum isolates was performed at the Fungus Testing Laboratory in the Department of Pathology at the University of Texas Health Science Center at San Antonio [14, 15] .
The interval between symptom onset and initiation of therapy was defined as the duration (in days) between the patient-reported time of onset of symptoms associated with GIB and the initiation of antifungal therapy or surgical excision. Deaths were attributable to GIB if no other cause was specified. When follow-up and outcome were not clearly documented, patients were considered to be alive if they survived the initial hospitalization associated with diagnosis of GIB.
Study Sample
We identified GIB cases reported at our institution (Mayo Clinic; Scottsdale, AZ) from January 1995 through March 2010 by searching our microbiology and pathology databases. The study was approved by the Mayo Clinic Institutional Review Board.
One of us (J. D. S.) contacted infectious diseases physicians in Arizona to identify additional cases. A second opinion on all suspected GIB cases in Arizona and on a case from Italy was obtained from pathologists at our institution (one of us [G. D. P.] and Thomas Colby, MD) because of their experience with GIB. Detailed clinical, diagnostic, and treatment information was abstracted from the medical records of our patients and was requested for external patients.
Additional case detection was sought by written communication with pathologists, infectious diseases specialists, and gastroenterologists throughout Arizona. We also contacted the ADHS, the Armed Forces Institute of Pathology, and the CDC. Health departments of adjoining states (ie, New Mexico, California, Utah, and Nevada) were queried, and the microbiology and pathology databases of Mayo Clinic campuses in Rochester, Minnesota, and Jacksonville, Florida, were searched.
We conducted a comprehensive search of the medical literature through March 2010 via PubMed, the US National Library of Medicine database, using the following search terms: Basidiobolus, Basidiobolus ranarum, Basidiobolus haptosporus, basidiobolomycosis, phycomycosis, entomophthoromycosis, mucormycosis, and zygomycosis in combination with the terms gastrointestinal, gastric, intestinal, abdominal, and disseminated. Articles were reviewed in detail by 2 of us (J. D. S. and H. R. V.) to determine whether cases met inclusion criteria. To identify additional cases, we reviewed references in these articles and abstracts of national and international meetings. Several cases were reported in .1 publication, and duplicates were diligently excluded.
Statistical Analysis
All data were entered manually and then assessed statistically with the Statistical Package for the Social Sciences (SPSS, version 18.0; SPSS [Chicago, IL; now owned by IBM {Somers, NY}]). Data integrity was assessed using SPSS Explore and Descriptive functions. Frequency distributions were evaluated for all categorical variables (eg, sex). Summary statistics included point estimates and SDs or ranges for all variables. Given the rarity of GIB, the small number of reported cases, and the heterogeneity of those cases, tests of statistical significance were not considered appropriate.
RESULTS
We identified 44 unique cases of GIB. Thirty-three cases (75%) had been reported previously in published articles (32 cases) or in abstract form (1 case) [2, [7] [8] [9] [10] [11] [12] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Nineteen (43%) were from the United States, and reports on 8 of these 19 had been published [8-11, 27-29, 32] The most common presenting symptom was abdominal pain. Other symptoms included abdominal distension, constipation, fever, weight loss, and palpable abdominal mass ( Table 2 ). The colon and rectum were most often involved (36 patients [82%]), followed by the small bowel (16 [36%] ), liver/gallbladder (13 [30%]), and stomach (6 [14%] ). Before confirmation of GIB, intraabdominal malignancy was the initial provisional diagnosis in most (19 [43%]) patients, followed by inflammatory bowel disease (7 [16%] ) and diverticulitis (5 [11%]) ( Table 2 ).
Imaging and Endoscopic Findings
Computed tomography (CT) of the abdomen and pelvis was performed in 30 patients (68%), whereas 1 patient each underwent barium swallow and abdominal ultrasonography. A mass in the colon (ie, cecum or ascending colon) or rectum was the most common finding (21 patients [48%]), followed by a mass in the liver (9 [20%]) or small bowel (5 [11%]) ( Figure 1 ). Eleven patients (25%) had bowel wall thickening, 2 had evidence of bowel perforation, and 2 had intraabdominal abscesses. Less frequently noted masses involved the gallbladder, pancreas, kidney, or retroperitoneum. Other sporadic findings noted on CT scans were duodenal-biliary fistula, hydronephrosis, and ascites.
Seventeen patients (39%) underwent colonoscopy, 4 (9%) had esophagogastroduodenoscopy, and 2 (5%) had sigmoidoscopy. Three patients (7%) had exploratory laparotomy. A mass involving part of the gastrointestinal tract was observed in 9 patients (20%), an ulcer in 9 (20%), bowel wall thickening in 7 (16%), and intestinal stricture in 6 (14%).
Laboratory Studies, Microbiologic Findings, and Surgical Pathology
Peripheral blood eosinophilia was noted in 26 (76%) of 34 patients; eosinophilia was significant in the majority, with a mean of 16% of the total white blood cell count (reference range, #6.6%). Specific serum antibodies to B. ranarum were detected in 8 (50%) of 16 patients who underwent testing [13] .
Basidiobolus 1997, 1999, and 2008) , Basidiobolus was uniformly resistant to amphotericin B and flucytosine. Two isolates demonstrated fluconazole resistance, and 1 isolate was resistant to caspofungin (only 1 tested). All 4 isolates were susceptible to itraconazole, 1 was susceptible to ketoconazole and miconazole, and 1 was also susceptible to voriconazole and posaconazole. Intraoperative visualization often revealed soft-to-firm masses involving the bowel, mesentery, or adjacent organs, as well as intraabdominal or retroperitoneal lymphadenopathy. Characteristic histopathologic findings of basidiobolomycosis were present in 43 patients (98%) (Figure 1 ) [11] . The involved portion of the gastrointestinal tract revealed diffuse mural thickening, with yellowish transmural nodules in the intestine and adjacent fat. The mucosal surface revealed prominent folds, focal hemorrhage, or ulceration. Granulomatous inflammation was centered in the muscularis propria, with extension into submucosa, subserosa, and adipose tissue. Granulomas demonstrated abundant multinucleated giant cells and palisading histiocytes around central necrosis or abscess formation. Thin-walled, broad fungal hyphae of Basidiobolus, with sparse septations, were often surrounded by a radiating, intensely eosinophilic cuff (Splendore-Hoeppli phenomenon). Abundant tissue eosinophilia and CharcotLeyden crystals were noted in some patients [11] .
GIB was diagnosed during surgical excision in 37 of 44 patients. Details were not available for 1 patient. Among the other 6, GIB was diagnosed based on autopsy (1 patient), positive results of stool culture (1), positive stool culture and colonoscopic biopsy (1), positive results of culture of a liver mass biopsy specimen (2), and colon mass biopsy (1).
Management, Follow-up, and Outcome
Most patients (37 [84%]) underwent surgical excision of the mass and any involved structures. Mean duration from symptom onset to surgical therapy was 83 days (range, 2-215 days) ( Table 3) . For the 7 patients who did not undergo surgery, a mean of 104 days (range, 30-300 days) elapsed before initiation of antifungal therapy.
Thirty-seven (86%) of 43 patients received antifungal therapy. In 25 patients for whom such information was available, mean duration of therapy was 8 months (range, 0-48 months). Itraconazole was the most commonly used antifungal agent (27 patients [73%]), followed by an amphotericin product (8 [22%] ).
Overall, 6 patients received no antifungal therapy. Four of them died: 3 died within 2 weeks of surgery, and 1 (who received a diagnosis in 2003) died in the emergency department with widespread intraabdominal basidiobolomycosis. The other 2 had no documented follow-up. All 6 underwent surgical [11] . Used with permission.) D, Histopathologic examination of the colon shows a dense fibrotic inflammatory reaction with scattered giant cells and lymphoid aggregates (hematoxylin-eosin; original magnification, 3100). E, Histopathologic examination of a tissue specimen from the colon shows a transversely cut hypha surrounded by an intensely eosinophilic cuff (Splendore-Hoeppli phenomenon), palisading histiocytes, eosinophils, multinucleated giant cells, and areas of fibrosis (hematoxylin-eosin stain; original magnification, 3200). F, Histopathologic examination of a tissue specimen reveals a broad, thin-walled, septated hyphae of Basidiobolus ranarum (Gomori methenamine silver stain; original magnification, 3400).
resection, and in 5 of these 6, onset of illness occurred between 1964 and 1993.
Patient follow-up and survival data were available for 41 patients; mean follow-up was 1.53 years (range, 0-13 years). Thirty-three (80%) of the 41 patients were alive, whereas 8 (20%) died as a result of their illness. Of the 8 who died, 4 each had symptom onset between 1964 and 1986 or between 2000 and 2006. Surgical resection had been undertaken in 6 of the 8. Of the 8 who died, 4 (including 3 with infection diagnosed before 1980) received no antifungal therapy; 3 received an amphotericin product; and 1 received itraconazole. One patient was from the United States, 2 each were from Brazil and Saudi Arabia, and 1 each was from Nigeria, Italy, and the Netherlands. Given the small number of patients who died, statistical analysis of risk factors for mortality was not appropriate.
DISCUSSION
The class Zygomycetes includes 2 orders of fungi of human significance, Mucorales and Entomophthorales. Genera from the order Mucorales (Rhizopus, Rhizomucor, Mucor, Absidia, Apophysomyces, Cunninghamella, and Saksenaea) are the etiologic agents for rapidly progressive, angioinvasive infections with rhinocerebral, orbital, pulmonary, disseminated, cutaneous, or (rarely) gastrointestinal involvement (mucormycosis) [33, 34] . Risk factors for mucormycosis include neutropenia, solid organ or bone marrow transplantation, uncontrolled diabetes mellitus, iron overload, metabolic acidosis, and deferoxamine therapy, with significant attributable morbidity and mortality [33] [34] [35] .
In contrast, entomophthoromycosis from B. ranarum and Conidiobolus coronatus involves indolent and slowly progressive subcutaneous infections in immunocompetent persons who reside in tropical and subtropical climates [34, 36] . Lesions (mostly from traumatic inoculation) are typically firm, painless, erythematous plaques with or without ulceration. Histopathologic analysis reveals broad fungal hyphae with granulomatous inflammation, eosinophilic infiltration, and the characteristic Splendore-Hoeppli phenomenon [11, 23] .
Within the past 3 decades, sporadic cases of gastrointestinal involvement with B. ranarum have been reported worldwide, and it appears to be an emerging infection in the southwestern United States.
Our analysis demonstrates that GIB occurs in patients from arid climates. Of patients with a GIB diagnosis, 84% had onset of symptoms after 1995. Patients were predominantly immunocompetent young men without underlying medical issues. In most, nonspecific and indolent signs and symptoms led to an initial consideration of abdominal malignancy. The most common finding on CT scan and endoscopy was an abdominal mass. Diagnosis was based on characteristic histopathologic findings except in 1 patient (described below). B. ranarum can be isolated in culture of tissue specimens in the majority of patients. Peripheral blood eosinophilia and serum serology can be useful diagnostic adjuncts.
Surgical excision of the mass encompassing the involved portion of the intraabdominal organ was undertaken in 84% of patients and led to the initial diagnosis of GIB in the majority. Overall, 37 (86%) of 43 patients received some form of antifungal therapy (usually itraconazole); 80% survived.
Notably, 17 (89%) of the 19 US patients with GIB were from Arizona, while 1 was from a Utah town bordering Arizona and 1 was a diabetic patient from Florida [8] . The first published report of a case of GIB in Arizona was in 1997 [28] . By March 1999, the ADHS had notified the CDC about 6 cases of GIB [9] . Subsequently, the CDC, in collaboration with Mayo Clinic in Scottsdale and the ADHS, conducted a case-control study (7 cases and 28 controls) to generate hypotheses about risk factors [10] . Potential risk factors included prior medical treatment for peptic ulcer disease and longer residence in Arizona. Of these 7 patients, 3 had diabetes, 1 had a history of pica, 1 was an avid gardener, 1 was a landscaper, 1 owned a trailer park in rural Arizona, and 1 lived in the same trailer park as the patient who owned it [10] .
B. ranarum can be found in soil; decaying vegetable matter; gastrointestinal tracts of amphibians (eg, frogs and toads), reptiles (eg, garden lizards and geckos), and fish; leaves from deciduous trees; bats; and feces of kangaroos and wallabies [36] . Fifty percent of trapped reptiles and amphibians from Florida were found to be colonized with Basidiobolus [1] . GIB is presumably acquired through ingestion. The emergence of GIB in Arizona within the past 2 decades remains unexplained. A portal of entry might be the natural reservoirs of B. ranarum in the southwestern desert (ie, soil and reptiles), activities associated with a higher risk of environmental exposure (eg, gardening, landscaping, or pica), unintentional ingestion of contaminated soil (especially near rivers and lakes), or consumption of contaminated fruits and vegetables. Host factors, such as (but not limited to) gastric acid suppression, gastrectomy, diabetes, and duration of residence in high-risk areas of endemicity may also contribute to risk [9, 10] . Increased awareness of GIB among healthcare professionals in areas of endemicity and appropriate specimen processing may lead to enhanced case detection and reporting. These hypotheses require careful scrutiny in future clinical trials. In earlier studies, in vitro susceptibilities of Basidiobolus were highly variable and isolate dependent [14, 15] . In our cohort, antifungal susceptibility testing was performed on 4 unique isolates of B. ranarum and identified uniform resistance to amphotericin B and flucytosine. Two strains were resistant to fluconazole, all 4 were susceptible to itraconazole, and 1 was also susceptible to miconazole and ketoconazole. The strain we isolated most recently was also susceptible to voriconazole and posaconazole but resistant to caspofungin. In this cohort, 2 patients treated with voriconazole had favorable responses. However, a correlation between antifungal susceptibility and clinical outcomes cannot be inferred at this time.
The most recent case of GIB at our institution was unique in several aspects. The patient was an obese man with diabetes who had had diarrhea for 18 months. He had undergone a Whipple procedure and several subsequent abdominal surgeries. Empirical oral vancomycin for presumed recurrent episodes of Clostridium difficile colitis had no benefit. Culture of his duodenal aspirate and stool fungal culture revealed growth of B. ranarum. An abdominal CT scan revealed no mass, bowel thickening, or other abnormality. Results of Basidiobolus serology were negative. He was treated with voriconazole, to which the isolate was susceptible. His stool returned to normal consistency within 3 weeks; results of stool fungal cultures were negative during voriconazole therapy. Diarrhea relapsed when voriconazole was discontinued after a 3-month course, and B. ranarum was again isolated from stool. Symptoms abated after resumption of voriconazole, which he continued to receive at 1-year follow-up.
Our study has several limitations. Cases of GIB in this cohort were reported between 1964 and 2010, which possibly contributed to the wide variety of outcomes. The small number of cases overall, many of which had incomplete information, precluded a valid analysis of risk factors for GIB and mortality. Also, length of follow-up was highly variable, and several patients were lost to follow-up. Antifungal therapy appears to be necessary for a favorable outcome. The exact contribution of surgical excision to the management of patients with GIB is unclear. Only 1 of the 8 patients who died was from the United States, and there were no significant differences between US cases and non-US cases (data not shown).
In conclusion, GIB is an indolent fungal infection mimicking malignancy or inflammatory bowel disease that occurs primarily in arid geographic regions. In the United States, it appears to be endemic in southwestern desert regions, where it was unrecognized before 1995. Risk factors for disease acquisition, environmental reservoirs, and predictors of poor outcomes merit further study. Awareness of its clinical presentation, radiographic and endoscopic findings, and characteristic histopathologic findings can facilitate prompt diagnosis and initiation of effective antifungal therapy. Persistent eosinophilia in patients presenting with any of the above clinical findings should alert clinicians to the possibility of GIB. Culture of involved tissues and stool with appropriate fungal growth media are useful diagnostic adjuncts. Itraconazole and possibly the newer azoles appear to be effective therapeutic agents. Surgical resection of the involved portion of the gastrointestinal tract may be required for obstructive symptoms or perforation.
Notes
